Is Pirfenidone a domestic drug or an imported drug?
Pirfenidone is a drug used to treat idiopathic pulmonary fibrosis (IPF). It was originally developed by the Japanese company Gilead and is an imported drug. It was first approved in Japan and subsequently launched in many countries and regions around the world. Domestically, pirfenidone is produced by multiple pharmaceutical companies and has been approved for marketing by the National Medical Products Administration (NMPA). Therefore, it can also be regarded as a category of imported drugs. However, since there are already domestic manufacturers, pirfenidone produced by some manufacturers is regarded as a domestic drug.
In the domestic market, the original drug of pirfenidone is produced by Gilead, with the brand name "Esbriet". Since its launch, the original drug has undergone multiple clinical verifications and safety assessments and has been widely used in the treatment of idiopathic pulmonary fibrosis. However, because they are more expensive and may be unaffordable for many patients, the emergence of generic drugs provides patients with a more economical option.

Currently, there are also generic pirfenidone drugs produced by many pharmaceutical companies on the domestic market, and the prices of these drugs are usually lower than those of the original drugs. The efficacy and safety of domestic generic drugs have passed strict review procedures to ensure that they have the same therapeutic effect as the original drugs. The emergence of domestic generic drugs has greatly reduced the cost of treatment for patients and helped more patients with poor economic conditions obtain necessary treatment.
In general, pirfenidone has both imported original drugs and approved domestic generic drugs. For patients, the choice between domestically produced drugs or imported drugs mainly depends on personal financial status, drug availability, and doctor's advice. No matter which form of medication is chosen, ensuring the quality and therapeutic effectiveness of the medication is paramount.
Reference materials:https://www.esbriet.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)